Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 5 (May)

1. Linking community pharmacy dispensing data to prescribing data of general practitioners.
   BMC Med Inform Decis Mak, 6: 18. [Abstract] [Full-text]
2. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy.
   J Clin Oncol, 24(13): 2079-83. [Abstract] [Full-text]
3. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
   J Clin Oncol, 24(13): 2059-64. [Abstract] [Full-text]
4. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
   J Clin Oncol, 24(13): 2044-51. [Abstract] [Full-text]
5. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
   J Clin Oncol, 24(13): 2038-43. [Abstract] [Full-text]
6. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
   J Clin Oncol, 24(13): 2019-27. [Abstract] [Full-text]
7. Type of menopause, patterns of hormone therapy use, and hot flashes.
   Fertil Steril, 85(5): 1432-40. [Abstract] [Full-text]
8. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond.
   Lancet Oncol, 7(5): 416-24. [Abstract] [Full-text]
9. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
   Lancet Oncol, 7(5): 379-91. [Abstract] [Full-text]
10. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart.
    Am J Obstet Gynecol, 194(5): e23-6. [Abstract] [Full-text]
11. Effect of the difference in vehicles on gene expression in the rat liver--analysis of the control data in the Toxicogenomics Project Database.
    Life Sci, 78(24): 2787-96. [Abstract] [Full-text]
12. Ocular syphilis in HIV-positive patients receiving highly active antiretroviral therapy.
    Am J Med, 119(5): 448.e21-5. [Abstract] [Full-text]
13. Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis.
    Arch Pediatr Adolesc Med, 160(5): 495-8. [Abstract] [Full-text]
14. Fibronectin is essential for hepatitis B virus propagation in vitro: may be a potential cellular target?
    Biochem Biophys Res Commun, 344(3): 757-64. [Abstract] [Full-text]
15. Glutathione S-transferase P1-1 expression modulates sensitivity of human kidney 293 cells to photodynamic therapy with hypericin.
    Arch Biochem Biophys, 449(1): 94-103. [Abstract] [Full-text]
16. Completion of therapy by Medicare patients with stage III colon cancer.
    J Natl Cancer Inst, 98(9): 610-9. [Abstract] [Full-text]
17. Use of postmenopausal hormone replacement therapy and risk of non-Hodgkin's lymphoma: a Danish population-based cohort study.
    Br J Cancer, 94(9): 1339-41. [Abstract] [Full-text]
18. Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II study.
    Br J Cancer, 94(9): 1263-6. [Abstract] [Full-text]
19. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
    Br J Cancer, 94(9): 1267-71. [Abstract] [Full-text]
20. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
    Br J Cancer, 94(9): 1293-9. [Abstract] [Full-text]
21. A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
    Br J Cancer, 94(9): 1281-6. [Abstract] [Full-text]
22. Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
    Br J Cancer, 94(9): 1237-44. [Abstract] [Full-text]
23. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    Br J Cancer, 94(9): 1287-92. [Abstract] [Full-text]
24. Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.
    Br J Cancer, 94(9): 1233-6. [Abstract] [Full-text]
25. E-Prescribing collaboration in Massachusetts: early experiences from regional prescribing projects.
    J Am Med Inform Assoc, 13(3): 239-44. [Abstract] [Full-text]
26. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Cancer, 106(10): 2208-17. [Abstract] [Full-text]
27. Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer.
    Cancer, 106(10): 2241-6. [Abstract] [Full-text]
28. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
    Blood, 107(10): 3832-40. [Abstract] [Full-text]
29. Intraperitoneal fluid therapy: an alternative to intravenous treatment in a patient with limited vascular access.
    Anaesthesia, 61(5): 502-4. [Abstract] [Full-text]
30. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy.
    Lancet, 367(9521): 1495-502. [Abstract] [Full-text]
31. Combining surgical ablation of retinal inflow and outflow vessels with photodynamic therapy for retinal angiomatous proliferation.
    Am J Ophthalmol, 141(5): 968-70. [Abstract] [Full-text]
32. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy.
    Am J Ophthalmol, 141(5): 958-60. [Abstract] [Full-text]
33. Effects of combination estrogen plus progestin hormone treatment on cognition and affect.
    J Clin Endocrinol Metab, 91(5): 1802-10. [Abstract] [Full-text]
34. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy.
    J Clin Endocrinol Metab, 91(5): 1691-7. [Abstract] [Full-text]
35. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study.
    J Clin Endocrinol Metab, 91(5): 1683-90. [Abstract] [Full-text]
36. Time course of pressure gradient response after first alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Am J Cardiol, 97(10): 1511-4. [Abstract] [Full-text]
37. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]).
    Am J Cardiol, 97(10): 1478-81. [Abstract] [Full-text]
38. Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome.
    Am J Cardiol, 97(10): 1473-7. [Abstract] [Full-text]
39. Postoperative pneumonia after major lung resection.
    Am J Respir Crit Care Med, 173(10): 1161-9. [Abstract] [Full-text]
40. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial.
    Pediatr Blood Cancer, 47(1): 22-9. [Abstract] [Full-text]
41. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
    Pediatr Blood Cancer, 47(1): 42-50. [Abstract] [Full-text]
42. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
    Pediatr Blood Cancer, 47(1): 37-41. [Abstract] [Full-text]
43. Successful treatment of the HIV-associated Burkitt lymphoma in a three-year-old child.
    Pediatr Blood Cancer, 47(1): 92-3. [Abstract] [Full-text]
44. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Report No. 4.
    Arch Ophthalmol, 124(5): 660-4. [Abstract] [Full-text]
45. Improving the management of pain in hospitalized adults.
    Arch Intern Med, 166(9): 1033-9. [Abstract] [Full-text]
46. Unopposed estrogen therapy and the risk of invasive breast cancer.
    Arch Intern Med, 166(9): 1027-32. [Abstract] [Full-text]
47. Off-label prescribing among office-based physicians.
    Arch Intern Med, 166(9): 1021-6. [Abstract] [Full-text]
48. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions.
    J Am Coll Cardiol, 47(9): 1741-53. [Abstract] [Full-text]
49. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
    CMAJ, 174(10): 1421-6. [Abstract] [Full-text]
50. Joe Burchenal and the birth of combination chemotherapy.
    Br J Haematol, 133(5): 493-503. [Abstract] [Full-text]
51. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.
    Chest, 129(5): 1274-81. [Abstract] [Full-text]
52. Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis.
    Chest, 129(5): 1267-73. [Abstract] [Full-text]
53. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    BJU Int, 97(6): 1300-8. [Abstract] [Full-text]
54. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    BJU Int, 97(6): 1184-9. [Abstract] [Full-text]
55. Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-kappaB activation or iNOS expression.
    Toxicology, 222(1): 125-31. [Abstract] [Full-text]
56. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
    Int J Cancer, 119(3): 706-11. [Abstract] [Full-text]
57. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with highly active antiretroviral therapy.
    J Infect Dis, 193(12): 1718-27. [Abstract] [Full-text]
58. Simulated clinical evaluation of four fluid warming devices*.
    Anaesthesia, 61(6): 571-5. [Abstract] [Full-text]
59. Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.
    Health Serv Res, 41(3): 837-55. [Abstract] [Full-text]
60. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
    N Engl J Med, 354(20): 2103-11. [Abstract] [Full-text]
61. Is thrombolytic therapy effective in elderly patients?
    Rejuvenation Res, 9(2): 358-61. [Abstract] [Full-text]
62. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.
    J Clin Oncol, 24(15): 2352-8. [Abstract] [Full-text]
63. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
    J Clin Oncol, 24(15): 2276-82. [Abstract] [Full-text]
64. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
    Oncology, 70(2): 147-53. [Abstract] [Full-text]
65. A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
    Oncology, 70(2): 134-40. [Abstract] [Full-text]
66. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
    Oncology, 70(2): 106-14. [Abstract] [Full-text]
67. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    J Clin Oncol, 24(15): 2237-44. [Abstract] [Full-text]
68. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.
    J Pharmacol Exp Ther, 317(3): 1246-53. [Abstract] [Full-text]
69. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    J Pharmacol Exp Ther, 317(3): 1372-81. [Abstract] [Full-text]
70. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
    J Pharmacol Exp Ther, 317(3): 1188-99. [Abstract] [Full-text]
71. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.
    J Pharmacol Exp Ther, 317(3): 1161-9. [Abstract] [Full-text]
72. Novel polymeric prodrug with multivalent components for cancer therapy.
    J Pharmacol Exp Ther, 317(3): 929-37. [Abstract] [Full-text]
73. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis--APART trial.
    Radiology, 239(3): 892-900. [Abstract] [Full-text]
74. The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature.
    Psychoneuroendocrinology, 31(6): 681-91. [Abstract] [Full-text]
75. The impact of prescribing safety alerts for elderly persons in an electronic medical record: an interrupted time series evaluation.
    Arch Intern Med, 166(10): 1098-104. [Abstract] [Full-text]
76. Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil.
    J Surg Oncol, 93(7): 529-33. [Abstract] [Full-text]
77. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.
    Blood, 107(11): 4207-13. [Abstract] [Full-text]
78. The impact of prophylactic antibiotics on postoperative infection complication in elective laparoscopic cholecystectomy: a prospective randomized study.
    Am J Surg, 191(6): 721-5. [Abstract] [Full-text]
79. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Cancer Chemother Pharmacol, 58(3): 402-7. [Abstract] [Full-text]
80. Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol, 58(3): 285-91. [Abstract] [Full-text]
81. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
    Cancer Chemother Pharmacol, 58(3): 343-7. [Abstract] [Full-text]
82. A multicenter phase II study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer: Kyushu thoracic oncology group trial.
    Cancer Chemother Pharmacol, 58(3): 368-73. [Abstract] [Full-text]
83. Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen.
    Cancer Chemother Pharmacol, 58(3): 292-305. [Abstract] [Full-text]
84. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin.
    Cancer Chemother Pharmacol, 58(3): 354-60. [Abstract] [Full-text]
85. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(3): 361-7. [Abstract] [Full-text]
86. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis.
    Invest Ophthalmol Vis Sci, 47(6): 2596-605. [Abstract] [Full-text]
87. A new method for measuring free drug concentration: retinal tissue as a biosensor.
    Invest Ophthalmol Vis Sci, 47(6): 2583-8. [Abstract] [Full-text]
88. Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model.
    Invest Ophthalmol Vis Sci, 47(6): 2498-507. [Abstract] [Full-text]
89. Polytetrafluoroethylene/polylactide-co-glycolide laminate containing dexamethasone allows delayed adjustable strabismus surgery in a rabbit model.
    Invest Ophthalmol Vis Sci, 47(6): 2485-90. [Abstract] [Full-text]
90. Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel.
    J Biomed Mater Res A, 78(1): 12-9. [Abstract] [Full-text]
91. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.
    Gynecol Oncol, 101(3): 495-8. [Abstract] [Full-text]
92. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature.
    Gynecol Oncol, 101(3): 464-9. [Abstract] [Full-text]
93. Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.
    Gynecol Oncol, 101(3): 429-35. [Abstract] [Full-text]
94. Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer.
    Gynecol Oncol, 101(3): 398-402. [Abstract] [Full-text]
95. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Science, 312(5777): 1171-5. [Abstract] [Full-text]
96. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial.
    Am J Cardiol, 97(11): 1573-7. [Abstract] [Full-text]
97. Epidemiology of aphasia attributable to first ischemic stroke: incidence, severity, fluency, etiology, and thrombolysis.
    Stroke, 37(6): 1379-84. [Abstract] [Full-text]
98. Hodgkin's lymphoma in adolescents.
    J Clin Oncol, 24(16): 2520-6. [Abstract] [Full-text]
99. Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
    J Clin Oncol, 24(16): 2480-9. [Abstract] [Full-text]
100. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines.
     J Clin Oncol, 24(16): 2444-7. [Abstract] [Full-text]
101. Effect of fluid resuscitation on acute skeletal muscle ischemia-reperfusion injury after hemorrhagic shock in rats.
     J Am Coll Surg, 202(6): 888-96. [Abstract] [Full-text]
102. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
     J Clin Oncol, 24(16): 2428-36. [Abstract] [Full-text]
103. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
     J Clin Oncol, 24(16): 2557-62. [Abstract] [Full-text]
104. Chemoradiotherapy in gallbladder cancer.
     J Surg Oncol, 93(8): 699-704. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.